New Technology Provides Insight into Targets and Mechanisms of Drug Action
A SLAS Discovery original research report
entitled “In Vitro Tissue Microarrays for Quick and Efficient Spheroid Characterization” describes a new technology that bridges the gap between clinical pathology assessment, high-content analysis and 3D cell cultures. With the spheroid microarray technique scientists can probe spheroid phenotype, multiplex readouts and analyze the results at the single cell level. The method arranges 66 spheroids in a gel array for paraffin-embedding, sectioning and immunohistochemistry. The process is rapid, automatable and uses 11 times fewer reagents compared to conventional workflows.
The authors demonstrate the advantages of their technique with a mixed array made up of spheroid models from 11 different cell lines. They stain all spheroids simultaneously and multiplex five different markers on adjacent sections. The staining, imaging and analysis are automated. The authors openly share their protocols, designs and ImageJ macros to enable other researchers to apply the technique for safety and efficacy testing as well as model optimization and characterization.
Three-dimensional cell cultures such as spheroids and organoids are being increasingly adopted in commercial and regulatory compound assessments. Along with organ-on-a-chip models these in vitro cultures are promising increased physiological relevance and therapeutic predictivity in both safety and efficacy screens.
The authors demonstrate the advantages of their technique with a mixed array made up of spheroid models from 11 different cell lines. They stain all spheroids simultaneously and multiplex five different markers on adjacent sections. The staining, imaging and analysis are automated. The authors openly share their protocols, designs and ImageJ macros to enable other researchers to apply the technique for safety and efficacy testing as well as model optimization and characterization.
Three-dimensional cell cultures such as spheroids and organoids are being increasingly adopted in commercial and regulatory compound assessments. Along with organ-on-a-chip models these in vitro cultures are promising increased physiological relevance and therapeutic predictivity in both safety and efficacy screens.